Although most of animals immunized with the DNA vaccines based in full-length NS3 survived virus challenge, 40% and 60% of pcTPANS3- and pcNS3-immunized mice, respectively, showed clinical signs of infection (Fig. 5). This evidence concerns the gene KRAS and infection.